These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 35263195)

  • 1. Evaluation of Adverse Effects in Nursing Mothers and Their Infants After COVID-19 mRNA Vaccination.
    Romero Ramírez DS; Suárez Hernández MI; Fernández Vilar AM; Rivero Falero M; Reyes Millán B; González Carretero P; Pérez MML; Carretero Pérez M; Martín Pulido S; Pera Villacampa L; García Bello MÁ; Mesa Medina OM; Roper S
    Breastfeed Med; 2022 May; 17(5):412-421. PubMed ID: 35263195
    [No Abstract]   [Full Text] [Related]  

  • 2. Breastfeeding Mother and Child Clinical Outcomes After COVID-19 Vaccination.
    Low JM; Lee LY; Ng YPM; Zhong Y; Amin Z
    J Hum Lact; 2022 Feb; 38(1):37-42. PubMed ID: 34713745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain.
    Lechosa-Muñiz C; Paz-Zulueta M; Mendez-Legaza JM; Irure-Ventura J; Cuesta González R; Calvo Montes J; López-Hoyos M; Llorca J; Cabero-Pérez MJ
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Maltezou HC; Hatziantoniou S; Theodoridou K; Vasileiou K; Anastassopoulou C; Tsakris A
    Vaccine; 2023 Mar; 41(14):2382-2386. PubMed ID: 36872145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
    Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
    BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers.
    McLaurin-Jiang S; Garner CD; Krutsch K; Hale TW
    Breastfeed Med; 2021 Sep; 16(9):702-709. PubMed ID: 34171971
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of COVID-19 Vaccination on Lactating Women: A Systematic Review of the Literature.
    Muyldermans J; De Weerdt L; De Brabandere L; Maertens K; Tommelein E
    Front Immunol; 2022; 13():852928. PubMed ID: 35464406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocarditis after vaccination against covid-19.
    Gellad WF
    BMJ; 2021 Dec; 375():n3090. PubMed ID: 34916217
    [No Abstract]   [Full Text] [Related]  

  • 12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study.
    Rogers A; Rooke E; Morant S; Guthrie G; Doney A; Duncan A; Mackenzie I; Barr R; Pigazzani F; Zutis K; MacDonald TM
    BMJ Open; 2022 Jun; 12(6):e060583. PubMed ID: 35649591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
    Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
    BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry.
    Bikdeli B; Jiménez D; Demelo-Rodriguez P; Galeano-Valle F; Porras JA; Barba R; Ay C; Malý R; Braester A; Imbalzano E; Rosa V; Lecumberri R; Siniscalchi C; Fidalgo Á; Ortiz S; Monreal M; For The Riete Investigators
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.